Targeting the IL33-NLRP3 axis improves therapy for experimental cerebral malaria.
Strangward P, Haley MJ, Albornoz MG, Barrington J, Shaw T, Dookie R, Zeef L, Baker SM, Winter E, Tzeng TC, Golenbock DT, Cruickshank SM, Allan SM, Craig A, Liew FY, Brough D, Couper KN.
Strangward P, et al.
Proc Natl Acad Sci U S A. 2018 Jul 10;115(28):7404-7409. doi: 10.1073/pnas.1801737115. Epub 2018 Jun 28.
Proc Natl Acad Sci U S A. 2018.
PMID: 29954866
Free PMC article.